Olmer Brooker, MD
Internal Medicine · El Paso, TXNPI 1952304297
Payments from drug & device makers
Across 102 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$198
- Merck$131
- Biohaven Pharmaceuticals, Inc.$126
- Pfizer$119
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$118
- GSK$111
- plus $875 from 21 others
What the payments were for
- Food & beverage$1,679100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $198 |
| Merck | 8 | $131 |
| Biohaven Pharmaceuticals, Inc. | 7 | $126 |
| Pfizer | 8 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $118 |
| GSK | 8 | $111 |
| Amarin Pharma, Inc. | 6 | $109 |
| Kowa Pharmaceuticals America, Inc. | 7 | $91 |
| AbbVie(2 entities) | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| AstraZeneca | 4 | $61 |
| Radius Health, Inc. | 4 | $58 |
| Novo Nordisk | 4 | $57 |
| Boehringer Ingelheim | 3 | $52 |
| Abbott | 2 | $45 |
| Sanofi Pasteur Inc. | 1 | $31 |
| Novartis | 2 | $26 |
| Seqirus USA Inc | 1 | $25 |
| Corcept Therapeutics | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Amgen | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Bayer | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,679 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 112 | $119,574 |
| MounjaroTirzepatide | 56 | $100,429 |
| OzempicSemaglutide | 60 | $95,575 |
| TrulicityDulaglutide | 36 | $63,746 |
| JardianceEmpagliflozin | 45 | $57,506 |
| EliquisApixaban | 48 | $51,534 |
| JanumetSitagliptin Phos/Metformin Hcl | 30 | $31,807 |
| RybelsusSemaglutide | 15 | $29,111 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $28,848 |
| FarxigaDapagliflozin Propanediol | 30 | $26,668 |
| ProliaDenosumab | 15 | $26,499 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $25,815 |
| LinzessLinaclotide | 22 | $24,184 |
| XareltoRivaroxaban | 30 | $23,680 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $22,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $131 | $180,230176 claims |
| Lilly USA, LLCMounjaro, Trulicity | $198 | $164,17592 claims |
| Novo NordiskOzempic, Rybelsus | $57 | $124,68675 claims |
| Boehringer IngelheimJardiance | $52 | $57,50645 claims |
| PfizerEliquis | $119 | $51,53448 claims |
| AbbVieLinzess, Synthroid | $83 | $28,34471 claims |
| AstraZenecaFarxiga | $61 | $26,66830 claims |
| AmgenProlia | $21 | $26,49915 claims |
| GSKTrelegy Ellipta | $111 | $25,81529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in El Paso
- Javier VasalloEl Paso$2.5M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.